GB9826662D0 - Controlled release formulation - Google Patents

Controlled release formulation

Info

Publication number
GB9826662D0
GB9826662D0 GBGB9826662.0A GB9826662A GB9826662D0 GB 9826662 D0 GB9826662 D0 GB 9826662D0 GB 9826662 A GB9826662 A GB 9826662A GB 9826662 D0 GB9826662 D0 GB 9826662D0
Authority
GB
United Kingdom
Prior art keywords
controlled release
release formulation
formulation
controlled
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9826662.0A
Other versions
GB2344287A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Priority to GB9826662A priority Critical patent/GB2344287A/en
Publication of GB9826662D0 publication Critical patent/GB9826662D0/en
Priority to TR2001/02273T priority patent/TR200102273T2/en
Priority to RU2001118040/15A priority patent/RU2233170C2/en
Priority to JP2000584909A priority patent/JP2002531411A/en
Priority to BR9915943-0A priority patent/BR9915943A/en
Priority to KR1020017006883A priority patent/KR20010089538A/en
Priority to SK755-2001A priority patent/SK7552001A3/en
Priority to PL99348575A priority patent/PL348575A1/en
Priority to PCT/GB1999/004045 priority patent/WO2000032218A1/en
Priority to EEP200100293A priority patent/EE200100293A/en
Priority to CZ20011893A priority patent/CZ20011893A3/en
Priority to CA002353798A priority patent/CA2353798A1/en
Priority to AU15732/00A priority patent/AU770676B2/en
Priority to HU0104943A priority patent/HUP0104943A3/en
Priority to IL14349699A priority patent/IL143496A0/en
Priority to EP99958357A priority patent/EP1140133A1/en
Priority to CN99815183A priority patent/CN1332635A/en
Priority to NZ511984A priority patent/NZ511984A/en
Priority to MXPA01005543A priority patent/MXPA01005543A/en
Publication of GB2344287A publication Critical patent/GB2344287A/en
Priority to NO20012636A priority patent/NO20012636L/en
Priority to ZA200104530A priority patent/ZA200104530B/en
Priority to HR20010421A priority patent/HRP20010421A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GB9826662A 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation Withdrawn GB2344287A (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
MXPA01005543A MXPA01005543A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii.
CZ20011893A CZ20011893A3 (en) 1998-12-03 1999-12-02 Pharmaceutical preparation, methods for treating health state and use of a peptide
AU15732/00A AU770676B2 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising GnRH-II
JP2000584909A JP2002531411A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising GNRH-II
BR9915943-0A BR9915943A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
KR1020017006883A KR20010089538A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
SK755-2001A SK7552001A3 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
PL99348575A PL348575A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
EEP200100293A EE200100293A (en) 1998-12-03 1999-12-02 Controlled release dosage form containing GnRH-II
TR2001/02273T TR200102273T2 (en) 1998-12-03 1999-12-02 Controlled release formulation containing GNRH-II.
CA002353798A CA2353798A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
RU2001118040/15A RU2233170C2 (en) 1998-12-03 1999-12-02 Composition with controlled-release comprising gnrh-ii
HU0104943A HUP0104943A3 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii and its use
IL14349699A IL143496A0 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
EP99958357A EP1140133A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii
CN99815183A CN1332635A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising GnRH-II
NZ511984A NZ511984A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising GnRH-II
NO20012636A NO20012636L (en) 1998-12-03 2001-05-29 Controlled release formulation comprising GNRH-II
ZA200104530A ZA200104530B (en) 1998-12-03 2001-06-01 Controlled release formulation comprising GNRH-II.
HR20010421A HRP20010421A2 (en) 1998-12-03 2001-06-01 Controlled release formulation comprising gnrh-ii

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation

Publications (2)

Publication Number Publication Date
GB9826662D0 true GB9826662D0 (en) 1999-01-27
GB2344287A GB2344287A (en) 2000-06-07

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9826662A Withdrawn GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation

Country Status (22)

Country Link
EP (1) EP1140133A1 (en)
JP (1) JP2002531411A (en)
KR (1) KR20010089538A (en)
CN (1) CN1332635A (en)
AU (1) AU770676B2 (en)
BR (1) BR9915943A (en)
CA (1) CA2353798A1 (en)
CZ (1) CZ20011893A3 (en)
EE (1) EE200100293A (en)
GB (1) GB2344287A (en)
HR (1) HRP20010421A2 (en)
HU (1) HUP0104943A3 (en)
IL (1) IL143496A0 (en)
MX (1) MXPA01005543A (en)
NO (1) NO20012636L (en)
NZ (1) NZ511984A (en)
PL (1) PL348575A1 (en)
RU (1) RU2233170C2 (en)
SK (1) SK7552001A3 (en)
TR (1) TR200102273T2 (en)
WO (1) WO2000032218A1 (en)
ZA (1) ZA200104530B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909814B1 (en) 2005-07-26 2015-06-24 Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) Peptides for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2013518115A (en) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
HUE035776T2 (en) 2011-06-22 2018-05-28 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides with glucocorticoid receptor activity
JP6392123B2 (en) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ CTP-based insulin analog for diabetes treatment
SG11201408347UA (en) 2012-06-14 2015-01-29 Ambrx Inc Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
AU2013277372B2 (en) 2012-06-21 2018-03-29 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting GIP receptor activity
JP6311708B2 (en) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
CN104789524A (en) * 2015-04-30 2015-07-22 四川大学 Osteoporotic rat primary osteoblasts isolated culture method and application thereof
WO2017024111A1 (en) 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
EA201991738A1 (en) * 2017-01-20 2020-02-11 Имьюн Систем Регулеишн Холдинг Аб NEW COMPOUNDS (IMMUNORELINS)
US11576910B2 (en) 2017-06-30 2023-02-14 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
JOP20200020B1 (en) 2017-08-03 2023-09-17 Amgen Inc Interleukin-21 muteins and methods of treatment
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP2020536507A (en) 2017-09-18 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Claudin 6 antibody and methods for treating cancer
CR20210319A (en) 2018-01-12 2021-07-27 Amgen Inc Anti-pd-1 antibodies and methods of treatment
US20200085776A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
MX2021011330A (en) 2019-03-20 2021-12-10 Univ California Claudin-6 antibodies and drug conjugates.
CA3102364A1 (en) * 2019-03-26 2020-10-01 Novel Pharma Inc. Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
MX2021013271A (en) 2019-04-30 2022-01-06 Inst De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors.
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
AU2020340442A1 (en) 2019-08-30 2022-03-03 Research Institute At Nationwide Children's Hospital Copper-ATSM for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
WO1997047743A1 (en) * 1996-06-13 1997-12-18 Zymogenetics, Inc. Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
ZA200104530B (en) 2002-06-04
GB2344287A (en) 2000-06-07
PL348575A1 (en) 2002-06-03
NZ511984A (en) 2002-11-26
AU1573200A (en) 2000-06-19
NO20012636D0 (en) 2001-05-29
CZ20011893A3 (en) 2002-05-15
WO2000032218A1 (en) 2000-06-08
SK7552001A3 (en) 2002-02-05
HUP0104943A2 (en) 2002-06-29
HRP20010421A2 (en) 2002-06-30
NO20012636L (en) 2001-07-12
KR20010089538A (en) 2001-10-06
TR200102273T2 (en) 2001-12-21
CA2353798A1 (en) 2000-06-08
CN1332635A (en) 2002-01-23
EE200100293A (en) 2002-08-15
RU2233170C2 (en) 2004-07-27
BR9915943A (en) 2001-08-21
IL143496A0 (en) 2002-04-21
JP2002531411A (en) 2002-09-24
EP1140133A1 (en) 2001-10-10
HUP0104943A3 (en) 2002-08-28
AU770676B2 (en) 2004-02-26
MXPA01005543A (en) 2003-07-14

Similar Documents

Publication Publication Date Title
GB9826662D0 (en) Controlled release formulation
EG24198A (en) Extended release formulation
SG71879A1 (en) Controlled release compositions
SG93831A1 (en) Polimeric controlled release compositions
GB2339000B (en) Release device
EP1107735A4 (en) Omeprazole formulation
HUP0203680A3 (en) Controlled release hydrocodone formulations
PL343021A1 (en) Formulations
SG71789A1 (en) Controlled release compositions
EG24226A (en) Formulation
IL135457A0 (en) Extended release formulation
SG72947A1 (en) Controlled release compositions
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AUPP279698A0 (en) Sustained release formulation
GB2334486B (en) Release unit
GB2322867B (en) Release agent
GB9810180D0 (en) Novel formulation
GB9815001D0 (en) Formulations
GB9815002D0 (en) Formulations
GB9927614D0 (en) Sterliant formulation
GB9711946D0 (en) Release devices
GB9816563D0 (en) Controlled release formulations
GB9404544D0 (en) Controlled release formulation
ZA983505B (en) Controlled release pesticidal compositions

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)